IMMVIRA
Immvira was founded in Shenzhen China in May of 2015 by Prof. Bernard Roizman of University of Chicago and Prof. Grace Zhou formerly a Research Associate Professor at University of Chicago, Prof. Thomas Shenk of Princeton University, Prof. Richard Whitley of University of Alabama, Prof. Ralph Weichselbaum of University of Chicago.
IMMVIRA
Industry:
Clinical Trials
Founded:
2015-01-01
Address:
Shenzhen, Guangdong, China
Country:
China
Website Url:
http://www.immvira-theravir.com
Total Employee:
1+
Status:
Active
Contact:
(0755)28291816
Total Funding:
90.49 M USD
Technology used in webpage:
SPF Microsoft Azure DNS China Telecom Tencent QQ Mail Xinnet DNS
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Genetron Health
Genetron Health is a world-leading expert in precision medicine.
Current Employees Featured
Founder
Investors List
GL Ventures
GL Ventures investment in Series C - Immvira
WinDigital Capital
WinDigital Capital investment in Series C - Immvira
Lanting Capital
Lanting Capital investment in Series C - Immvira
Octagon Capital Partners
Octagon Capital Partners investment in Series C - Immvira
Hillhouse Capital Group
Hillhouse Capital Group investment in Series C - Immvira
OrbiMed
OrbiMed investment in Series C - Immvira
Greater Bay Area Homeland Development Fund
Greater Bay Area Homeland Development Fund investment in Series C - Immvira
China Merchants Capital
China Merchants Capital investment in Series C - Immvira
Shanghai Healthcare Capital
Shanghai Healthcare Capital investment in Series B - Immvira
Cowin Capital
Cowin Capital investment in Series B - Immvira
Key Employee Changes
Date | New article |
---|---|
2020-07-01 | Immvira Announces the Appointment of Carl Yeung as Chief Financial Officer |
Official Site Inspections
http://www.immvira-theravir.com Semrush global rank: 4.26 M Semrush visits lastest month: 2.73 K
Unable to get host informations!!!

More informations about "Immvira"
ไบฆ่ฏบๅพฎ-ImmVira
ImmVira is a biotechnology company focused on development of new generation novel drug vectors driven by clinical benefits in oncology and non-oncology fields. Leveraging naturally โฆSee details»
Immvira - Crunchbase Company Profile & Funding
Immvira was founded in Shenzhen China in May of 2015 by Prof. Bernard Roizman of University of Chicago and Prof. Grace Zhou formerly a Research Associate Professor at University of โฆSee details»
ImmVira - LinkedIn
ImmVira | 223 followers on LinkedIn. A company focusing on developing aboard range of anti-cancer therapies | VISION ABOVE AND BEYOND Immvira was founded in May of 2015 by โฆSee details»
ๅ ณไบๆไปฌ - immviragroup.com
ImmVira is a biotechnology company focused on development of new generation novel anti-cancer drug vectors driven by clinical benefits in oncology and non-oncology fields. Leveraging โฆSee details»
Immvira Pharma Co. Ltd | Reagan-Udall Foundation
ImmVira is a biotechnology company focused on development of new generation novel drug vectors driven by clinical benefits in oncology and non-oncology fields. T3011 is a replication โฆSee details»
Immvira Company Profile | Management and Employees List
Immvira Profile and History ImmVira is a biotechnology company focused on genetically modified oncolytic viruses as potential cancer therapeutics. The company has developed science, โฆSee details»
ImmVira | VentureRadar
Immvira's mission is to develop a broad range of anti-cancer therapies based on genetically engineered viruses and augmented by cancer specific immune factors or chemotherapeutic โฆSee details»
ImmVira Company Profile - Office Locations, Competitors ... - Craft
ImmVira is a company that develops biopharmaceutical technology in the field of immunotherapy. The company provides medical solutions to treat cancer and tumor. It offers a product called โฆSee details»
Press Release - immviragroup.com
SHENZHEN, China, March 15, 2024 /PRNewswire/ -- ImmVira has recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for oncolytic โฆSee details»
Immvira Co. Ltd. - BioCentury Company Profiles - BCIQ
Apr 21, 2023 Immvira Co. Ltd. - BioCentury Company Profiles for the biopharma industrySee details»
ImmVira and Shanghai Pharma Announce Clinical Collaboration โฆ
Aug 6, 2020 Immvira Co., Ltd. was founded on May 18, 2015 by six scientists in the field of "tumor's oncolytic immunity" from the United States. The company develops innovative drugs โฆSee details»
ImmVira enters clinical development in combination therapy of โฆ
Apr 19, 2022 MVR-T3011, ImmVira's proprietary 3-in-1oncolytic herpes simplex virus ("oHSV"), is a novel genetically engineered oHSV which aims to achieve the most favorable profile of โฆSee details»
ImmVira enters clinical development in combination therapy of โฆ
Apr 20, 2022 ImmVira is a biotechnology company focused on development of new generation novel anti-cancer drug vectors. Our advanced engineering created vectors that are highly โฆSee details»
Immvira moves intravenous oHSV into phase II for cancer
Nov 13, 2023 Immvira Group Co. plans to progress its intravenous oncolytic herpes simplex virus (oHSV) MVR-T3011-IV to phase II trials after completing a phase I study in the U.S. in โฆSee details»
ImmVira's New-Generation Vector Poised to Enable CAR-T โฆ
Jan 25, 2022 ImmVira will continue to adhere to a science-driven, original innovations and patient-focused philosophy, to continue research and development of new viral vectors drugs. โฆSee details»
ImmVira and Shanghai Pharma Announce Clinical Collaboration
Aug 6, 2020 Immvira Co., Ltd. was founded on May 18, 2015 by six scientists in the field of "tumor's oncolytic immunity" from the United States. The company develops innovative drugs โฆSee details»
ImmVira's MVR-T3011 IV completed first 2 cohorts dose โฆ
ImmVira's CEO Dr. Guoying Zhou said, "The good news from MVR-T3011 IV clinical study is inspiring. Leveraging our proprietary OvPENS new drug R&D platform, we will continue to โฆSee details»
FDA Fast Tracks ImmVira's Oncolytic Herpes Simplex Virus Therapy โฆ
Mar 21, 2024 ImmVira's oncolytic herpes simplex virus (oHSV) therapy MVR-T3011 IT for intratumoral injection has been granted Fast Track designation by the FDA to treat patients โฆSee details»
ImmVira Says IV Administration of Oncolytic Herpes Simplex Virus โฆ
Jul 21, 2022 Shenzhen ImmVira announced its IV oncolytic herpes simplex virus (oHSV) therapy showed promising biodistribution after completing the first three dose escalations in a US trial โฆSee details»
ImmVira's MVR-T3011 Obtained NMPA's Approval for Intravenous ...
SHENZHEN, China, Aug. 6, 2021 /PRNewswire/ -- ImmVira announced that as a global first, its lead oncolytic virus therapy program MVR-T3011 IV (also known as T3011), obtained approval โฆSee details»